Concepedia

Publication | Open Access

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

DOIFull Paper Access

265

Citations

24

References

2020

Year

Robert F. Kushner, Salvatore Calanna, Melanie J. Davies, Dror Dicker, W. Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette S. Thomsen, Thomas A. Wadden, Sean Wharton,
Obesity

Abstract

The STEP program evaluates the efficacy and safety of semaglutide 2.4 mg subcutaneously once weekly in a broad population. The trials will provide insights on WM in people with obesity with and without type 2 diabetes and on long-term follow-up.

References

YearCitations

Page 1